Thursday, 9 May 2013

profit by disease

It is not in the financial interests of the pharmaceutical industry to prevent or cure common diseases but rather manage them in the most profitable way.
The maintenance and expansion of diseases is a precondition for the financial growth of the pharmaceutical "disease business".
1   The pharmaceutical industry is an investment industry driven by the profits of its shareholders. Improving human health is not the driving force of this industry.
2   The pharmaceutical investment industry was artificially created and strategically developed over an entire century by the same investment groups that control the global petrochemical and chemical industries.
3   The huge profits of the pharmaceutical industry are based on the patenting of new drugs. These patents essentially allow drug manufacturers to arbitrarily define the profits for their products.
4   The marketplace for the pharmaceutical industry is the human body – but only for as long as the body hosts diseases. Thus, maintaining and expanding diseases is a precondition for the growth of the pharmaceutical industry.
5   A key strategy to accomplish this goal is the development of drugs that merely mask symptoms while avoiding the curing or elimination of diseases. This explains why most prescription drugs marketed today have no proven efficacy and merely target symptoms.
6    To further expand their pharmaceutical market, the drug companies are continuously looking for new applications (indications) for the use of drugs they already market. For example, Bayer’s pain pill Aspirin is now taken by 50 million healthy US citizens under the illusion it will prevent heart attacks.
7    Another key strategy to expand pharmaceutical markets is to cause new diseases with drugs. While merely masking symptoms short term, most of the prescription drugs taken by millions of patients today cause a multitude of new diseases as a result of their known long-term side effects. For example, all cholesterol-lowering drugs currently on the market are known to increase the risk of developing cancer – but only after the patient has been taking the drug for several years.
8   The known deadly side effects of prescription drugs are the fourth leading cause of death in the industrialized world, surpassed only by the number of deaths from heart attacks, cancer and strokes (Journal of the American Medical Association, April 15, 1998). This fact is no surprise either, because drug patents are primarily issued for new synthetic molecules. All synthetic molecules need to be detoxified and eliminated from the body, a system that frequently fails and results in an epidemic of severe and deadly side effects.
9   While the promotion and expansion of diseases increase the market of the pharmaceutical investment industry - prevention and root cause treatment of diseases decrease long-term profitability; therefore, they are avoided or even obstructed by this industry.
10   Worst of all, the eradication of diseases is by its very nature incompatible with and diametrically opposed to the interests of the pharmaceutical investment industry. The eradication of diseases now considered as potential drug markets will destroy billions of investment dollars and eventually will eliminate this entire industry.
11   Vitamins and other effective natural health therapies that optimize cellular metabolism threaten the pharmaceutical "business with disease" because they target the cellular cause of today’s most common diseases - and these natural substances cannot be patented.12
Throughout the more than one hundred year existence of the pharmaceutical industry, vitamins and other essential nutrients, with defined functions as cofactors in cellular metabolism, have been the fiercest competition and the greatest threat to the long-term success of the pharmaceutical investment business.
13   Vitamins and other effective natural health therapies that effectively prevent diseases are incompatible with the very nature of the pharmaceutical "business with disease."14 To protect the strategic development of its investment business against the threat from effective, natural and non-patentable therapies, the pharmaceutical industry has – over an entire century - used the most unscrupulous methods, such as:


Withholding life-saving health information from millions of people. It is simply unacceptable that today so few know that the human body cannot produce vitamin C and lysine, two key molecules for connective tissue stability and disease prevention.


Discrediting natural health therapies. The most common way is through global PR campaigns organized by the Pharma-Cartel that spread lies about the alleged side effects of natural substances – molecules that have been used by Nature for millennia.


Banning by law the dissemination of information about natural health therapies. To that end, the pharmaceutical industry has placed its lobbyists in key political positions in key markets and leading drug export nations.
15   The pharmaceutical "business with disease" is the largest deception and fraud business in human history. The product "health" promised by drug companies is not delivered to millions of patients. Instead, the "products" most often delivered are the opposite: new diseases and frequently, death. [I think the petroleum industry would have to appear somewhere on the list - i.e., for suppression of free energy.]
16   The survival of the pharmaceutical industry is dependent on the elimination by any means of effective natural health therapies. These natural and non-patentable therapies have become the treatment of choice for millions of people despite the combined economic, political and media opposition of the world’s largest investment industry.

Marcia Angell Speaks on Drug Companies Epic Profits

- Dr. Marcia Angell, former editor in chief of the New England Journal of Medicine

"The combined profits for the 10 drug companies in the Fortune 500 ($35.9 billion) were more than the profits for all the other 490 businesses put together ($33.7 billion) in 2002. Over the past two decades the pharmaceutical industry has moved very far from its original high purpose of discovering and producing useful new drugs. Now primarily a marketing machine to sell drugs of dubious benefit, this industry uses its wealth and power to co-opt every institution that might stand in its way, including the US Congress, the FDA, academic medical centers, and the medical profession itself." (ABC Lateline)

Check out her book if you like:
The Truth About the Drug Companies:
How They Deceive Us and What to Do About It
Marcia Angell

Marcia Angell, M.D. (born April 20, 1939 in Knoxville, TN) is an American physician, author, and the first woman to serve as editor-in-chief of the New England Journal of Medicine (NEJM). She currently is a Senior Lecturer in the Department of Social Medicine at Harvard Medical School in Boston, Massachusetts.